{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"To determine the overall response rate in patients with recurrent and metastatic adenoid cystic carcinoma treated with amivantamab. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.\"","groups":[{"description":"Amivantamab weekly for the first cycle and biweekly thereafter.\n\nAmivantamab: Patients will receive amivantamab at 1050mg weekly for the first cycle and biweekly thereafter (1400mg for patients ≥80kg).","id":"OG000","title":"Amivantamab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"3 patients were unevaluable and excluded from efficacy analyses for discontinuing amivantamab treatment before first restaging. Thus, 18 subjects were included for analyses.","reportingStatus":"POSTED","timeFrame":"2 years","title":"Overall Response Rate Measured by RECIST Criteria","type":"PRIMARY","unitOfMeasure":"Participants"}